Cargando…

Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat

Hypertension plays an important role in the development and progression of chronic kidney disease. Studies to date, with mineralocorticoid receptor antagonists (MRA), have demonstrated varying degrees of results in modifying the development of renal fibrosis. This study aimed to investigate whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leader, Catherine J., Kelly, Darren J., Sammut, Ivan A., Wilkins, Gerard T., Walker, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243196/ https://www.ncbi.nlm.nih.gov/pubmed/32441493 http://dx.doi.org/10.14814/phy2.14448

Ejemplares similares

Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model
por: Leader, Catherine J., et al.
Publicado: (2019)

The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat
por: Leader, C. J., et al.
Publicado: (2021)

Spironolactone alleviates schizophrenia-related reversal learning in Tcf4 transgenic mice subjected to social defeat
por: Stephan, Marius, et al.
Publicado: (2022)

Cardiac Magnetic Resonance Assessment of Interstitial Myocardial Fibrosis and Cardiomyocyte Hypertrophy in Hypertensive Mice Treated With Spironolactone
por: Coelho‐Filho, Otavio R., et al.
Publicado: (2014)

Renal Fibrosis mRNA Classifier: Validation in Experimental Lithium-Induced Interstitial Fibrosis in the Rat Kidney
por: Marti, Hans-Peter, et al.
Publicado: (2016)

Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan
por: Makhlough, Atieh, et al.
Publicado: (2014)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
por: Sacharczuk, Wioletta, et al.
Publicado: (2023)

Spironolactone in pulmonary arterial hypertension: results of a cross-over study
por: Safdar, Zeenat, et al.
Publicado: (2020)

Association of spironolactone treatment and arterial stiffness and cardiovascular disease in hypertensive patients
por: Zeng, Fanfang, et al.
Publicado: (2019)

Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change
por: Aryal, Sudeep R., et al.
Publicado: (2021)

Effects of spironolactone in spontaneously hypertensive adult rats subjected to high salt intake
por: Baldo, Marcelo Perim, et al.
Publicado: (2011)

Spironolactone Lowers Portal Hypertension by Inhibiting Liver Fibrosis, ROCK-2 Activity and Activating NO/PKG Pathway in the Bile-Duct-Ligated Rat
por: Luo, Wei, et al.
Publicado: (2012)

Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients
por: Sun, Zuoya, et al.
Publicado: (2023)

Spironolactone-Induced Unilateral Gynecomastia
por: Veeregowda, Sahana Hadihalli, et al.
Publicado: (2018)

Furosemide and spironolactone doses and hyponatremia in patients with heart failure
por: Velat, Ivan, et al.
Publicado: (2020)

Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
por: Safdar, Zeenat, et al.
Publicado: (2021)

Association between Use of Spironolactone and Risk of Stroke in Hypertensive Patients: A Cohort Study
por: Cai, Xintian, et al.
Publicado: (2022)

Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study – a randomized controlled trial
por: Oliveras, Anna, et al.
Publicado: (2016)

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
por: Williams, Bryan, et al.
Publicado: (2018)

Spironolactone alleviates myocardial fibrosis via inhibition of Ets-1 in mice with experimental autoimmune myocarditis
por: Wang, Wen-Ke, et al.
Publicado: (2022)

The effect of spironolactone on diastolic function in haemodialysis patients
por: Hauser, T., et al.
Publicado: (2021)

Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study
por: Parthasarathy, Hari K, et al.
Publicado: (2007)

Effect of spironolactone on pain responses in mice
por: Abdel-Salam, Omar M.E., et al.
Publicado: (2010)

Spironolactone in cardiovascular disease: an expanding universe?
por: Funder, John W.
Publicado: (2017)

Imatinib and spironolactone suppress hepcidin expression
por: Mleczko-Sanecka, Katarzyna, et al.
Publicado: (2017)

Furosemide/spironolactone: Hypotension: case report
Publicado: (2022)

Prorenin independently causes hypertension and renal and cardiac fibrosis in cyp1a1-prorenin transgenic rats
por: Zhou, Guangyu, et al.
Publicado: (2018)

Spironolactone Reduces Severity of Obstructive Sleep Apnea in Patients with Resistant Hypertension: a Preliminary Report
por: Gaddam, Krishna, et al.
Publicado: (2009)

Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis
por: Chen, Cong, et al.
Publicado: (2020)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

Type 4 Renal Tubular Acidosis (RTA) Induced by Spironolactone Use in Secondary Adrenal Insufficiency
por: Santos, Claudia Villatoro, et al.
Publicado: (2021)

Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
por: Peeters, Laura E. J., et al.
Publicado: (2022)

Fibrosis following Acute Skeletal Muscle Injury: Mitigation and Reversal Potential in the Clinic
por: Gardner, Tyler, et al.
Publicado: (2020)

DRESS Syndrome Secondary to Spironolactone with Atypical Presentation
por: Bains, Anupama, et al.
Publicado: (2020)

Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy
por: Han, Jae Yong, et al.
Publicado: (2022)

Spironolactone for the treatment of acne in women, a retrospective study of 110 patients()()()
por: Charny, J.W., et al.
Publicado: (2017)

Local Inhibition of Indoleamine 2,3-Dioxygenase Mitigates Renal Fibrosis
por: Jensen, Camilla Grønkjær, et al.
Publicado: (2021)

Effect of Spironolactone in Resistant Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
por: Václavík, Jan, et al.
Publicado: (2014)

The Dose-Dependent Effects of Spironolactone on TGF-β1 Expression and the Vulnerability to Atrial Fibrillation in Spontaneously Hypertensive Rats
por: Tang, Mirong, et al.
Publicado: (2021)

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
por: Agarwal, Rajiv, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_391krpk40aepgoh96cmak18tj0